Related Experiment Video

Updated: Jun 11, 2025

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.6K

Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia

Xuan L Tang1, Amanda J Hooper1,2, John R Burnett1,2

  • 1Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.

Expert Opinion on Investigational Drugs
|October 5, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
APOC3ApoC-IIIapoC-III inhibitorhypertriglyceridemiaplozasiransiRNAtriglyceride

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.4K

Related Experiment Videos

Last Updated: Jun 11, 2025

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
08:53

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

7.6K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.4K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K

Articles linked to this work by shared authors, journal, and citation graph.

Birth prevalence and characterisation of congenital hyperinsulinism in Western Australia over two decades.

Journal of pediatric endocrinology & metabolism : JPEM·2026

Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

Pathology·2026

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Expert opinion on investigational drugs·2025

Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community.

European journal of human genetics : EJHG·2025

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Expert opinion on investigational drugs·2025

PUTRA-CV study protocol: a multicentre observational study of ethnic-specific genetic variants and dietary patterns in relation to lipoprotein(a) levels and their association with coronary artery disease severity in Malaysian adults.

BMJ open·2025

Zovegalisib for PIK3CA-driven vascular and lymphatic malformations: a drug evaluation.

Expert opinion on investigational drugs·2026

Targeting the proteasome in Leishmania donovani: developments from preclinical to Phase I and ii trials.

Expert opinion on investigational drugs·2026

Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers.

Expert opinion on investigational drugs·2026

Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma.

Expert opinion on investigational drugs·2026

Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density.

Expert opinion on investigational drugs·2026

Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products.

Expert opinion on investigational drugs·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us